NYSE - Nasdaq Real Time Price USD

Stryker Corporation (SYK)

325.50 -2.95 (-0.90%)
At close: May 6 at 4:00 PM EDT
327.00 +1.50 (+0.46%)
Pre-Market: 6:58 AM EDT
Loading Chart for SYK
DELL
  • Previous Close 328.45
  • Open 330.30
  • Bid 326.00 x 1200
  • Ask --
  • Day's Range 324.59 - 331.00
  • 52 Week Range 249.98 - 361.41
  • Volume 1,717,319
  • Avg. Volume 1,248,210
  • Market Cap (intraday) 123.999B
  • Beta (5Y Monthly) 0.91
  • PE Ratio (TTM) 37.16
  • EPS (TTM) 8.76
  • Earnings Date Aug 1, 2024 - Aug 5, 2024
  • Forward Dividend & Yield 3.20 (0.98%)
  • Ex-Dividend Date Mar 27, 2024
  • 1y Target Est 379.41

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries. This segment also offers spinal implant products comprising cervical and thoracolumbar systems that include fixation, minimally invasive and interbody systems used in spinal injury, complex spine and degenerative therapies. The MedSurg and Neurotechnology segment offers surgical equipment, and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, clinical communication and workflow solutions, and other medical device products that are used in various medical specialties, as well as patient and caregiver safety technologies. This segment also provides neurosurgical, neurovascular and craniomaxillofacial implant products, which include products used for minimally invasive endovascular procedures; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke; and craniomaxillofacial implant products, including cranial, maxillofacial, and chest wall devices, as well as dural substitutes and sealants. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Portage, Michigan.

www.stryker.com

52,000

Full Time Employees

December 31

Fiscal Year Ends

Recent News: SYK

Performance Overview: SYK

Trailing total returns as of 5/6/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

SYK
8.94%
S&P 500
8.61%

1-Year Return

SYK
15.51%
S&P 500
25.25%

3-Year Return

SYK
32.92%
S&P 500
24.31%

5-Year Return

SYK
80.42%
S&P 500
75.88%

Compare To: SYK

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: SYK

Valuation Measures

Annual
As of 5/6/2024
  • Market Cap

    124.00B

  • Enterprise Value

    134.46B

  • Trailing P/E

    37.16

  • Forward P/E

    27.47

  • PEG Ratio (5yr expected)

    2.77

  • Price/Sales (ttm)

    5.97

  • Price/Book (mrq)

    6.47

  • Enterprise Value/Revenue

    6.41

  • Enterprise Value/EBITDA

    25.99

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    16.03%

  • Return on Assets (ttm)

    7.23%

  • Return on Equity (ttm)

    18.64%

  • Revenue (ttm)

    20.96B

  • Net Income Avi to Common (ttm)

    3.36B

  • Diluted EPS (ttm)

    8.76

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    2.41B

  • Total Debt/Equity (mrq)

    69.89%

  • Levered Free Cash Flow (ttm)

    2.29B

Research Analysis: SYK

Analyst Price Targets

345.00
379.41 Average
325.50 Current
406.00 High
 

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell
 

Earnings

Consensus EPS
 

Company Insights: SYK

Fair Value

325.50 Current
 

Dividend Score

0 Low
SYK
Sector Avg.
100 High
 

Hiring Score

0 Low
SYK
Sector Avg.
100 High
 

Insider Sentiment Score

0 Low
SYK
Sector Avg.
100 High
 

Research Reports: SYK

  • Weekly Stock List

    Innovation may be hard to define but, to borrow from former U.S. Supreme Court Justice Potter Stewart, you know it when you see it. The United States economy is full of innovation. It has to be. Manufacturing industries that dominated the economy decades ago - textiles, televisions, even automobiles, to a large degree - have moved overseas, where costs are lower. Yet the U.S. economy is at its largest point in history and still growing. If U.S. corporations weren't innovating, creating new products and services, and moving into new markets and applications, the domestic economy would be contracting, not expanding, and capital would not be flooding into the country. Particularly at this juncture of the market and economic cycles, when uncertainty is high due to high inflation and rising interest rates, we look to innovative companies to navigate the challenges. At Argus, a 90-year-old independent research firm that has innovated a time or two in its long history, we have focused on four types of innovative companies: Industry Disruptors; First to Market; New Product Specialists; and Product & Process Perfectors. Here are some examples of companies, featured in our Innovation Theme Model Portfolio.

     
  • Analyst Report: Stryker Corporation

    Stryker designs, manufactures, and markets an array of medical equipment, instruments, consumable supplies, and implantable devices. The product portfolio includes hip and knee replacements, endoscopy systems, operating room equipment, embolic coils, hospital beds and gurneys, and spinal devices. Stryker remains one of the three largest competitors in reconstructive orthopedic implants and holds the leadership position in operating room equipment. Just over one fourth of Stryker's total revenue currently comes from outside the United States.

    Rating
    Price Target
     
  • The Argus Innovation Model Portfolio

    The United States economy is full of innovation. It has to be. Manufacturing industries that dominated the economy decades ago - textiles, televisions, even automobiles to a large degree - have moved overseas, where labor and materials costs are lower. Yet the U.S. economy, even during the pandemic and the current period of high inflation, has expanded to record levels. If U.S. corporations weren't innovating, creating new products (such as vaccines and AI) and services (such as Zoom calls) and moving into new markets, the domestic economy would not be growing, and capital would not be flooding into the country. The current high level of the U.S. dollar relative to currencies around the world attests to the confidence that global investors have in the durable and innovative U.S. economy.

     
  • Weekly Stock List

    We see what we believe are some great opportunities right now in Healthcare -- and we like the sector overall. Argus Director of Research Jim Kelleher, CFA, recently completed his quarterly sector review and raised Healthcare sector to Over-Weight from Market-Weight. The healthcare environment is undergoing rapid transitions, and we now see an unfolding period of significant promise and opportunity. Our newly-favored stance is based on resumption of deferred medical procedures and significant new quality-of-life drugs and treatments. The category is broad and has underperformed the S&P 500 over the past year. The Healthcare sector ETF (XLV) is up 15% over the past year compared to a gain of 31% for the S&P 500. We see opportunity here to pick up some steady companies, with big brands and solid financials. These companies are science-focused and enhance lives. They are innovators. In our list this week, we look across several subsectors within the Healthcare sector and pull out some leaders we like. These stocks also are included in our Focus List and Model Portfolios, as noted below.

     

People Also Watch